文献速递抗栓抗凝管理药物不良反应与药物警戒

比伐芦定与肝素在成人和儿童ECMO患者中的Meta分析

Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis.
PubMed 文献 · Br J Clin Pharmacol · 2022-02-14

该Meta分析纳入9项回顾性队列研究共994例ECMO患者,比较比伐芦定与普通肝素的抗凝效果。比伐芦定与较低的大出血、回路血栓、卒中和院内死亡风险相关,且提高脱机存活率,但儿童亚组未见显著获益,部分结果敏感性分析不稳健。

要点

  • 比伐芦定较肝素降低大出血(RR 0.32)、回路血栓(RR 0.57)和院内死亡(RR 0.82)风险。
  • 成人亚组中比伐芦定降低回路血栓和院内死亡风险,儿童亚组无显著差异。
  • 卒中、脱机存活和院内死亡结果在留一法敏感性分析中不稳健,需谨慎解读。

核心结论

  • 比伐芦定可能是需要ECMO的成人和儿童患者中普通肝素的潜在替代抗凝选择。

研究设计与样本

  • 检索Embase、PubMed、Cochrane图书馆、ClinicalTrials.gov、CNKI和万方数据库至2021年6月15日,纳入随机对照试验和观察性研究,最终纳入9项回顾性队列研究共994例患者。

主要发现

  • 与普通肝素相比,比伐芦定与大出血风险降低相关(RR 0.32,95%CI 0.22-0.49)。
  • 比伐芦定与ECMO回路血栓风险降低相关(RR 0.57,95%CI 0.43-0.74)。
  • 比伐芦定与卒中风险降低相关(RR 0.52,95%CI 0.29-0.95)。
  • 比伐芦定与院内死亡风险降低相关(RR 0.82,95%CI 0.69-0.99),并提高ECMO脱机存活率(RR 1.18,95%CI 1.03-1.34)。
  • 汇总风险估计未显示与临床血栓事件显著相关(RR 0.69,95%CI 0.45-1.07)。

临床怎么用

  • 在成人和儿童ECMO患者中,比伐芦定可考虑作为普通肝素的替代抗凝方案,但需结合患者个体情况。

局限性

  • 纳入研究均为回顾性队列研究,存在固有偏倚风险。
  • 留一法敏感性分析提示卒中、脱机存活和院内死亡结果需谨慎解读。
  • 儿童亚组中比伐芦定对回路血栓和院内死亡的获益不显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Unfractionated heparin (UFH) has been the primary anticoagulant of choice on extracorporeal membrane oxygenation (ECMO). However, it is debatable whether bivalirudin (BIV), a direct thrombin inhibitor, may be considered a better alternative anticoagulant option. METHODS: We searched Embase, Pubmed, Cochrane library, Clinicaltrials.gov, CNKI and Wanfang databases up to 15 June 2021. Randomized controlled trials and observational studies were considered eligible for inclusion. Random-effects meta-analyses, including subgroup analyses, were conducted. RESULTS: A total of 9 studies containing 994 patients were enrolled. All articles were retrospective cohort studies. Compared with UFH, BIV was associated with lower risks of major bleeding (risk ratio [RR]: 0.32, 95% confidence interval [CI] 0.22-0.49), ECMO in-circuit thrombosis (RR: 0.57, 95% CI 0.43-0.74), stroke (RR: 0.52, 95% CI 0.29-0.95) and in-hospital mortality (RR: 0.82, 95% CI 0.69-0.99), and higher rates of survival to ECMO decannulation (RR: 1.18, 95% CI 1.03-1.34). Pooled risk estimates did not show a significant association with clinical thrombotic events (RR: 0.69, 95% CI 0.45-1.07). Moreover, BIV was associated with a lower risk of ECMO in-circuit thrombosis and in-hospital mortality in the adult subgroup but not in the paediatric subgroup. However, leave-one-out sensitivity analyses indicated that the results of stroke, survival to ECMO decannulation and in-hospital mortality should be interpreted with caution. CONCLUSION: BIV appears to be a potential alternative to UFH in paediatric and adult patients requiring ECMO.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Li MJ, Shi JY, Zhang JH, et al. Bivalirudin vs. heparin in paediatric and adult patients on extracorporeal membrane oxygenation: A meta-analysis. Br J Clin Pharmacol. 2022. PMID: 35098565. doi:10.1111/bcp.15251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。